The β1-Adrenergic Receptor Contributes to Sepsis-Induced Imm… : Critical Care Medicine

1Université de Lorraine, Inserm U1116, DCAC, Nancy, France.

2Département de Médecine Intensive – Réanimation, Université d’Angers, CHU Angers, Angers, France.

3Faculty of Medicine, Université de Lorraine, Stress Immunity Pathogens Laboratory, EA 7300, Vandoeuvre-lès-Nancy, France.

4Bloomsbury Institute of Intensive Care Medicine, University College London, London, United Kingdom.

5Department of Biopathology, Faculty of Medicine, Université de Lorraine, CHRU de Nancy, Inserm U1256, Vandœuvre-lès-Nancy, France.

6Université de Lorraine, CHRU de Nancy, Service de médecine intensive et réanimation Brabois, Inserm U116, F-CRIN-INI-CRCT, Vandœuvre-lès-Nancy, France.

7Department d’Anesthésie-Réanimation, Université de Paris, APHP, CHU Lariboisière, FHU PROMICE, Inserm U942, Paris, France.

8F-CRIN-INI-CRCT, Vandœuvre-lès-Nancy, France.

*See also p. 1415.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website (http://journals.lww.com/ccmjournal).

Drs Durand and Kimmoun contributed to study concept and design. Drs Durand and Louis were involved in experiments (Dr Durand was involved in all experiments and Dr Louis was involved in flow cytometry supervision). Drs. Labat and Kimmoun, with the help of François Husson, contributed to statistical analysis. Drs. Durand, Asfar, Frippiat, Singer, Glenn Chousterman, and Kimmoun contributed to drafting of the article. All authors were involved in critical revision of the article. All authors read and approved the final article.

Supported, in part, by the Fondation pour la Recherche Médicale (FRM grant number ECO20170637495 to Dr Durand.)

dr Durand’s institution funding received from the Fondation pour la Recherche Médicale (FRM grant number ECO20170637495). dr Asfar received funding from GlaxoSmithKline. dr Singer’s institution funding received from Biotest, Deltex, and NewB; he received funding from Biotest, Biomerieux, Fresenius, General Electric, Nestle, NewB Diagnostics, Pfizer, and Shionogi. Drs. Singer and Levy received funding from Amomed. dr Singer received funding from Roche. dr Levy received funding from Gettinge, Novartis, Baxter, Amomed, Orion, and Sanofi. dr Kimmoun received funding from Aguettant. dr Glenn Chousterman received fees as a member of an advisory board from Roche Diagnostics. The remaining authors have disclosed that they do not have any potential conflicts of interest.

Raw data and statistical analyzes of all presented results are available at the following: https://osf.io/nz5u9/ or DOI 10.17605/OSF.IO/NZ5U9. dr Durand takes responsibility for the integrity of the data.

For information regarding this article, email: [email protected]